World No Tobacco Day 2016
31 May is World No Tobacco Day. It is organized by the World Health Organization to draw attention to the health risks associated with the use of tobacco and what can still be done to reduce tobacco consumption around the world.Here we focus on a Cochrane Review of a medical intervention - nicotine receptor partial agonists for smoking cessation - and what the available evidence tells us about its effectiveness. Cochrane Review provides more support for medication as long-term aid to quitting smokingWhen people stop smoking, they experience cravings to smoke and unpleasant mood changes. Nicotine receptor partial agonists a...
Source: Cochrane News and Events - May 31, 2016 Category: Information Technology Authors: mumoquit at cochrane.org Source Type: news
Europe lifts warning on Pfizer smoking cessation drug
LONDON (Reuters) - European regulators have lifted a warning on Pfizer's smoking cessation drug Champix - called Chantix in the United States - after a clinical study concluded it did not appear to increase the risk of neuropsychiatric side effects. (Source: Reuters: Health)
Source: Reuters: Health - May 23, 2016 Category: Consumer Health News Tags: healthNews Source Type: news
Taking prescription medication to help stop smoking is more successful long term
A new NIHR Cochrane Review has confirmed that varenicline (branded as Champix), the most commonly used prescription medication used to treat nicotine addiction, more than doubles the likelihood of stopping people smoking in the long term, compared to those who don’t use medications to help them quit. When people stop smoking they experience cravings to... (Source: NIHR Evaluation, Trials and Studies News)
Source: NIHR Evaluation, Trials and Studies News - May 12, 2016 Category: American Health Source Type: news
The FDA Should Remove Warning Label On The Smoking Cessation Drug Chantix
By removing the black box label for Chantix, the FDA will encourage the broader use of this drug and enable more and more people to quit. It is an action that needs to be taken. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - May 5, 2016 Category: Pharmaceuticals Authors: John LaMattina Source Type: news
The FDA Needs To Change The Label For The Smoking Cessation Drug, Chantix
By removing the black box label for Chantix, the FDA will encourage the broader use of this drug and enable more and more people to quit. It is an action that needs to be taken. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - May 5, 2016 Category: Pharmaceuticals Authors: John LaMattina Source Type: news
Pfizer’s EAGLES trial finds Chantix safe in smokers with psychiatric disorders
Pfizer has reported positive results from EAGLES, a multi-centre, parallel-group, post-authorisation safety study / post-marketing requirement (PASS / PMR), which was conducted in 16 countries in collaboration with GlaxoSmithKline. (Source: Drug Development Technology)
Source: Drug Development Technology - April 24, 2016 Category: Pharmaceuticals Source Type: news
Stop smoking drugs not linked to rise in psychiatric side effects
Varenicline and bupropion do not increase rates of depression, anxiety or suicide ideation Related items from OnMedicaCombining varenicline with nicotine patch boosts quit ratesHospitals ‘should provide free e-cigarettes to patients’Teens who vape, likely to try the real thing a year onTobacco giants start legal challenge against plain packaging in UKStop smoking drug not linked to heart attacks or depression (Source: OnMedica Latest News)
Source: OnMedica Latest News - April 24, 2016 Category: UK Health Source Type: news
Elevated Psychiatric Risk Not Observed with Varenicline and Bupropion (FREE)
By Kelly Young
Edited by Susan Sadoughi, MD, and André Sofair, MD, MPH
The smoking cessation medications varenicline and bupropion aren't associated with increased risk for moderate-to-severe neuropsychiatric adverse events, suggests an industry-funded study requested by the FDA. Both drugs carry a … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - April 24, 2016 Category: Primary Care Source Type: news
Chantix, Wellbutrin Found Safe in Smokers with Psych Disorders (CME/CE)
(MedPage Today) -- No increase in psychiatric adverse events for drug, patch users versus placebo (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - April 24, 2016 Category: Primary Care Source Type: news
Smoking cessation medications do not appear to increase risk of neuropsychiatric side effects, study finds
The smoking cessation medications varenicline and bupropion do not appear to increase the incidence of serious neuropsychiatric side effects compared to placebo, according to a new study. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - April 23, 2016 Category: Science Source Type: news
Anti-Smoking Drugs Don’t Risk Mental Health: Study
Meds like Chantix and Wellbutrin may be safer to use than smokers often realize, research suggests (Source: WebMD Health)
Source: WebMD Health - April 23, 2016 Category: Consumer Health News Source Type: news
No Link Between Anti-Smoking Drugs, Mental Health Issues: Study
Meds like Chantix and Wellbutrin may be safer to use than smokers often realize, research suggests
Source: HealthDay
Related MedlinePlus Pages: Medicines, Mental Disorders, Quitting Smoking (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - April 22, 2016 Category: Consumer Health News Source Type: news
No Link Between Anti-Smoking Drugs, Mental Health Issues: Study
Meds like Chantix and Wellbutrin may be safer to use than smokers often realize, research suggests (Source: The Doctors Lounge - Psychiatry)
Source: The Doctors Lounge - Psychiatry - April 22, 2016 Category: Psychiatry Authors: webmaster at doctorslounge.com Tags: Pharmacy, Psychiatry, Preventive Medicine, News, Source Type: news
No Link Between Anti-Smoking Drugs, Mental Health Issues: Study
FRIDAY, April 22, 2016 -- The anti-smoking drugs Chantix (varenicline) and Wellbutrin (bupropion) don't appear to raise the risk of serious mental health disorders such as depression, anxiety and suicidal thoughts, a new study suggests.
"Clinical... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 22, 2016 Category: Journals (General) Source Type: news
Smoking cessation drugs do not elevate risk of serious neuropsychiatric adverse effects
(University of California - San Diego) Compared to the nicotine patch and a placebo, the smoking cessation aids varenicline (marketed as Chantix in the US) and bupropion (Zyban) do not show a significant increase in neuropsychiatric adverse events, reports an international team of researchers in a study published online April 22 in the journal The Lancet. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 22, 2016 Category: Global & Universal Source Type: news
